title: Leucine affects the metabolism of valine by isolated perfused rat hearts: relation to branched-chain amino acid antagonism.
abstract: This study was conducted to determine the effects of different concentrations of leucine on the transport, transamination and oxidation of valine and on incorporation of valine into heart proteins in the isolated perfused rat heart. Valine metabolism was studied in rat hearts perfused with medium containing glucose and graded levels of L-leucine. In transport studies L-phenylalanine was also tested. Uptake of L-[1-14C]valine (0.2 mmol/L) was significantly reduced (-50%) by inclusion of 0.2 mmol/L phenylalanine or leucine, and by -70% by inclusion of 1.0 mmol/L phenylalanine or leucine in the perfusate. Transamination of valine decreased by 37 and 48%, and oxidation of valine by 53 and 71%, respectively, when 0.2 or 1.0 mmol/L leucine was included in the perfusate. Tissue concentrations of valine decreased by 43, 48 and 62% in the presence of 0.2, 0.5 and 1.0 mmol/L leucine, respectively; tissue concentrations of leucine, glutamate and alanine increased approximately 11-fold, 1.2-fold and 0.5-fold, respectively, when 1.0 mmol/L leucine was present in the perfusate. Addition of 0.2-1.0 mmol/L leucine did not affect incorporation of valine into heart proteins. We conclude that 1) competition among large neutral amino acids for transport into heart occurs at physiological concentrations of these amino acids in plasma; 2) inhibition of valine uptake by leucine can limit the rate of valine catabolism in heart; and 3) depletion of tissue valine concentration by an excess of leucine did not affect the rate of protein synthesis.
authors.affiliation: Department of Nutritional Sciences, College of Agricultural and Life Sciences, University of Wisconsin-Madison 53706, USA.
authors.forename: N
authors.initials: N
authors.lastname: Torres
authors.forename: A R
authors.initials: AR
authors.lastname: Tovar
authors.forename: A E
authors.initials: AE
authors.lastname: Harper
mesh_terms: D042942:3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide); D000409:Alanine / Q000032:analysis; D000597:Amino Acids, Branched-Chain / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000818:Animals; D001667:Binding, Competitive; D004305:Dose-Response Relationship, Drug; D018698:Glutamic Acid / Q000032:analysis; D066298:In Vitro Techniques; D007658:Ketone Oxidoreductases / Q000378:metabolism; D007930:Leucine / Q000032:analysis / Q000494:pharmacology*; D008297:Male; D009097:Multienzyme Complexes / Q000378:metabolism; D009206:Myocardium / Q000737:chemistry / Q000378:metabolism*; D010649:Phenylalanine / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors; D000637:Transaminases / Q000378:metabolism; D014633:Valine / Q000032:analysis / Q000378:metabolism* / Q000493:pharmacokinetics
chemical_list: D000597:Amino Acids, Branched-Chain; D009097:Multienzyme Complexes; D018698:Glutamic Acid; D010649:Phenylalanine; D007658:Ketone Oxidoreductases; D042942:3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide); D000637:Transaminases; C019798:branched-chain-amino-acid transaminase; D007930:Leucine; D014633:Valine; D000409:Alanine